254 related articles for article (PubMed ID: 36253800)
1. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.
Liu Z; Yang H; Chen Z; Jing C
Hereditas; 2022 Oct; 159(1):40. PubMed ID: 36253800
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.
Zhu K; Liu X; Deng W; Wang G; Fu B
Hereditas; 2022 Feb; 159(1):13. PubMed ID: 35125116
[TBL] [Abstract][Full Text] [Related]
4. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
5. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
[TBL] [Abstract][Full Text] [Related]
7. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
8. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
9. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
[TBL] [Abstract][Full Text] [Related]
10. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
11. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
12. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
13. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
14. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
15. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
16. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
17. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
18. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
20. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.
Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F
Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
